Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2026)

Sarepta Therapeutics' Raw Materials history runs 11 years deep, the most recent figure standing at $137.0 million for Q1 2026.

• In Q1 2026, Raw Materials fell 54.19% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at $137.0 million (down 54.19% YoY), while the FY2025 annual figure was $141.3 million, down 49.55% from the prior year.
• Raw Materials was $137.0 million for Q1 2026 at Sarepta Therapeutics, down from $141.3 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $325.5 million in Q3 2025 to a low of $41.3 million in Q1 2022.
• Historically, Raw Materials has averaged $176.0 million across 5 years, with a median of $150.0 million in 2024.
• Biggest YoY gain for Raw Materials was 523.55% in 2022; the steepest drop was 77.86% in 2022.
• A 5-year view of Raw Materials shows it stood at $59.2 million in 2022, then surged by 126.36% to $134.0 million in 2023, then jumped by 109.05% to $280.0 million in 2024, then tumbled by 49.55% to $141.3 million in 2025, then fell by 3.06% to $137.0 million in 2026.
• The last three Raw Materials figures came in at $137.0 million (Q1 2026), $141.3 million (Q4 2025), and $325.5 million (Q3 2025), per Business Quant data.